120 related articles for article (PubMed ID: 7725373)
1. Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors.
Bonetti A; Franceschi T; Apostoli P; Messori A; Sperotto L; Cetto GL; Molino A; Leone R
Ther Drug Monit; 1995 Feb; 17(1):25-32. PubMed ID: 7725373
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin pharmacokinetics in elderly patients.
Bonetti A; Franceschi T; Apostoli P; Cetto GL; Recaldin E; Molino A; Leone R
Ther Drug Monit; 1994 Oct; 16(5):477-82. PubMed ID: 7846745
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors.
Dominici C; Petrucci F; Caroli S; Alimonti A; Clerico A; Castello MA
J Clin Oncol; 1989 Jan; 7(1):100-7. PubMed ID: 2909663
[TBL] [Abstract][Full Text] [Related]
4. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer.
Erlichman C; Soldin SJ; Thiessen JJ; Sturgeon JF; Fine S
Cancer Chemother Pharmacol; 1987; 19(1):75-9. PubMed ID: 3815729
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy.
Goel R; Andrews PA; Pfeifle CE; Abramson IS; Kirmani S; Howell SB
Eur J Cancer; 1990 Jan; 26(1):21-7. PubMed ID: 2156545
[TBL] [Abstract][Full Text] [Related]
6. Two-cycle cisplatin kinetics in patients with ovarian and mammary cancer.
Leone R; Benoni G; Apostoli P; Bonetti A; Griso C; Fracasso ME
Ther Drug Monit; 1987 Dec; 9(4):374-7. PubMed ID: 3424403
[TBL] [Abstract][Full Text] [Related]
7. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
Motzer RJ; Reed E; Perera F; Tang D; Shamkhani H; Poirier MC; Tsai WY; Parker RJ; Bosl GJ
Cancer; 1994 Jun; 73(11):2843-52. PubMed ID: 7514956
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
[TBL] [Abstract][Full Text] [Related]
9. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
Leone R; Fracasso ME; Soresi E; Cimino G; Tedeschi M; Castoldi D; Monzani V; Colombi L; Usari T; Bernareggi A
Cancer Chemother Pharmacol; 1992; 29(5):385-90. PubMed ID: 1312907
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.
Ikeda K; Terashima M; Kawamura H; Takiyama I; Koeda K; Takagane A; Sato N; Ishida K; Iwaya T; Maesawa C; Yoshinari H; Saito K
Jpn J Clin Oncol; 1998 Mar; 28(3):168-75. PubMed ID: 9614438
[TBL] [Abstract][Full Text] [Related]
11. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.
Fisch MJ; Howard KL; Einhorn LH; Sledge GW
Clin Cancer Res; 1996 Jun; 2(6):1063-6. PubMed ID: 9816268
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patients.
Boffetta P; Fichtinger-Schepman AM; Weiderpass E; van Dijk-Knijnenburg HC; Stoter G; van Oosterom AT; Keizer HJ; Fosså SD; Kaldor J; Roy P
Anticancer Drugs; 1998 Feb; 9(2):125-9. PubMed ID: 9510497
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of platinum in cancer patients treated with cisplatin at different doses.
Fracasso ME; Apostoli P; Benoni G; Bonetti A; Griso C; Leone R
Drugs Exp Clin Res; 1987; 13(6):367-72. PubMed ID: 3652926
[TBL] [Abstract][Full Text] [Related]
15. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
Reece PA; Stafford I; Russell J; Gill PG
J Clin Oncol; 1986 Sep; 4(9):1392-8. PubMed ID: 3746376
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of cumulative very high dose of cisplatin in chemotherapy resistant solid tumors.
Tebano MT; Carlini P; Loizzo A; Luzi M; Petrucci F; Alimonti A; Caroli S
Ann Ist Super Sanita; 1995; 31(3):351-7. PubMed ID: 8712579
[TBL] [Abstract][Full Text] [Related]
17. cis-Diamminedichloroplatinum(II) given in low-dose continuous infusion with concurrent radiotherapy to patients affected by inoperable lung carcinoma: a pharmacokinetic approach.
Morazzoni F; Canevali C; Zucchetti M; Caroli S; Alimonti A; Petrucci F; Giudice G; Masoni E; Bedini AV
J Cancer Res Clin Oncol; 1998 Jan; 124(1):37-43. PubMed ID: 9498833
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
[TBL] [Abstract][Full Text] [Related]
19. Platinum pharmacokinetics in sulphur-crested cockatoos (Cacatua galerita) following single-dose cisplatin infusion.
Filippich LJ; Bucher AM; Charles BG
Aust Vet J; 2000 Jun; 78(6):406-11. PubMed ID: 10920780
[TBL] [Abstract][Full Text] [Related]
20. Platinum in blood mononuclear cells from patients after cisplatin therapy.
Sunderman FW; Sporn J; Hopfer SM; Sweeney KR; Chakraborty NG; Greenberg B
Ann Clin Lab Sci; 1990; 20(6):379-84. PubMed ID: 2073087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
